425: Waters Corporation to Combine with BD's Biosciences & Diagnostic Solutions Business in Strategic Merger

Waters Corporation announced a definitive agreement to combine with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business, aiming to create a leading life science and diagnostics company focused on regulated, high-volume testing.

Summary

• Waters Corporation has entered into an agreement to combine with Becton, Dickinson and Company's (BD) Biosciences & Diagnostic Solutions business, which will operate as Augusta SpinCo Corporation (SpinCo).
• The combination is intended to create a leading entity in life science and diagnostics, specializing in regulated, high-volume testing.
• The transaction is expected to close around the end of the first quarter of calendar year 2026.
• The combined company will be led by Udit, the current CEO of Waters, and will welcome approximately 8,000 new colleagues from BD's business.
• Waters' headquarters will remain in Milford, Massachusetts, while BD's Biosciences & Diagnostic Solutions business has an international presence, including sites in the U.S. (Baltimore, San Diego, San Jose), Europe, China, and Japan.
• The transaction is subject to required regulatory approvals, Waters shareholder approval, and other customary closing conditions.
• An integration planning team will be formed with leaders from both companies to manage the transition.

Sentiment

Score: 9

Explanation: The document expresses highly positive sentiment, framing the business combination as a 'pivotal moment' and a 'game-changing opportunity' that will create a 'leader' and unlock 'full potential,' while also highlighting Waters' current 'position of strength.'

Positives

• Combines two best-in-class innovators to create a life science and diagnostics leader.
• Strategic expansion into multiple high-growth adjacencies, including bioseparations, bioanalytical characterization, and multiplex diagnostics.
• Leverages Waters' operational excellence playbook to unlock the full potential of BD's Biosciences & Diagnostic Solutions business through improved instrument replacement, service plan attachment, e-commerce adoption, and launch excellence.
• Brings together highly complementary innovative technologies and commercial channels.
• Waters is entering this new chapter from a position of strength due to progress over the past five years.

Risks

• One or more closing conditions, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all.
• A governmental entity may prohibit, delay, or refuse to grant approval for the transaction, or may require conditions, limitations, or restrictions.
• Required approval by Waters' stockholders may not be obtained.
• The proposed transaction may not be completed on the terms or in the time frame expected, or at all.
• Unexpected costs, charges, or expenses may result from the proposed transaction.
• Uncertainty of the expected financial performance of the combined company following completion of the transaction.
• Failure to realize the anticipated benefits of the proposed transaction, including as a result of delays in completing the transaction or integrating the businesses.
• Difficulties and delays in the combined company achieving revenue and cost synergies.
• Inability of the combined company to retain and hire key personnel.
• Occurrence of any event that could give rise to termination of the proposed transaction.
• Stockholder litigation or other litigation, settlements, or investigations may affect the timing or occurrence of the transaction or result in significant costs.
• Evolving legal, regulatory, and tax regimes could impact the transaction.
• Changes in general economic and/or industry-specific conditions or volatility from tariffs.
• Actions by third parties, including government agencies, could affect the transaction.
• The anticipated tax treatment of the proposed transaction may not be obtained.
• Greater than expected difficulty in separating SpinCo's business from other BD businesses.
• Disruption of management time from ongoing business operations due to the pendency of the transaction.
• Other effects of the pendency of the transaction on relationships with employees, customers, suppliers, or other counterparties.

Future Outlook

The combined company aims to be a leader in life science and diagnostics, expanding into high-growth adjacencies such as bioseparations, bioanalytical characterization, and multiplex diagnostics. Waters expects to leverage its operational excellence to unlock the full potential of BD's Biosciences & Diagnostic Solutions business, improving instrument replacement, service plan attachment, e-commerce adoption, and launch excellence.

Management Comments

• "Today marks a pivotal moment for Waters as we announce an agreement to combine BDs Biosciences & Diagnostic Solutions business with Waters."
• "This combination brings together two best-in-class innovators to create a life science and diagnostics leader focused on regulated, high-volume testing."
• "Waters is entering this exciting new chapter from a position of strength."
• "Waters has the playbook and operational excellence to unlock the full potential of BDs Biosciences & Diagnostics business."
• "This combination will also advance our strategy to expand into multiple high-growth adjacencies."
• "Post-close, I will serve as CEO of the combined company, welcoming approximately 8,000 new colleagues."
• "We are committed to communicating updates as we proceed through the integration planning process."
• "This is a game-changing opportunity, and we are ready for it!"

Industry Context

This announcement signifies a significant consolidation and strategic expansion within the life science and diagnostics industry. By combining Waters' expertise with BD's Biosciences & Diagnostic Solutions, the new entity aims to establish itself as a leader in regulated, high-volume testing, and to penetrate high-growth areas like bioseparations, bioanalytical characterization, and multiplex diagnostics, reflecting a broader industry trend towards integrated solutions and specialized high-value segments.

Management Changes

Stakeholder Impact

• Shareholders: Requires Waters shareholder approval, and potential for stockholder litigation related to the transaction.
• Employees: Approximately 8,000 new colleagues will join the combined company; risks related to retention of key personnel and disruption of management time.
• Customers: Emphasis on continued support for customers during the transition.
• Suppliers/Counterparties: Potential for effects on relationships due to the pendency of the transaction.

Next Steps

• Form an integration planning team with leaders from both Waters and BD's Biosciences & Diagnostic Solutions business.
• Communicate updates to employees and stakeholders as the integration planning process proceeds.
• Remain focused on current priorities and supporting customers until the transaction closes.
• Waters, SpinCo, and BD intend to file relevant materials with the U.S. Securities and Exchange Commission (SEC), including a registration statement on Form S-4 by Waters and a registration statement on Form 10 by SpinCo.
• Waters shareholders will need to approve the transaction.

Key Dates

Keywords

Waters Corporation, Becton Dickinson, BD, Biosciences, Diagnostic Solutions, Augusta SpinCo Corporation, SpinCo, Merger, Acquisition, Business Combination, Life Science, Diagnostics, Flow Cytometry, Microbiology, Molecular Diagnostics, Bioseparations, Bioanalytical Characterization, Multiplex Diagnostics, SEC Filing